返回
D
Domenica Lorusso
Humanitas University
77H指数
968论文数
3.8W被引数
收录论文 247
发表时间
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancerPRIMA/ENGOT-OV26/GOG-3012试验中 niraparib 一线维持治疗新诊断晚期卵巢癌患者的患者报告结局更新及疾病进展对健康相关生活质量的影响
Gynecologic Oncology
IF4.1
Final overall survival (OS) results from the phase 3 ROSELLA trial: Relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (PROC) (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223)ROSELLA三期试验的最终总生存期(OS)结果:relacorilant联合nab-紫杉醇对比nab-紫杉醇单药治疗铂耐药卵巢癌(PROC)患者的疗效(GOG-3073,ENGOT-ov72,APGOT-Ov10和LACOG-0223)
Gynecologic Oncology
IF4.1

